Boardroom Alpha
8-K primary document
TNON · Current Report (Form 8-K) · Filed June 12, 2026

Tenon Medical Inc8-K exhibit

ea029465701ex10-1.htm

Exhibit 10.1

 

 

Consulting Agreement Amendment A

 

This Consulting Agreement Amendment is dated May 7, 2026 (the “Effective Date”), by and between Richard Ferrari and Tenon Medical, Inc. (collectively, the “Parties”).

 

WHEREAS the Parties entered into a Consulting Agreement on May 7, 2021 (the “Original Contract”).

 

WHEREAS the Parties hereby agree to extend the term of the Original Contract in accordance with the terms of the Original Contract as well as the terms provided herein.

 

In consideration of the mutual covenants contained herein, the Parties mutually agree as follows:

 

The parties agree to extend the Original Contract for an additional (1) year, which will begin immediately upon the effective date of this agreement, May 7, 2026, and will end on May 6, 2027.

 

The attached Exhibit A shall supersede the previous Exhibits and amendments effective May 7, 2026.

 

All other terms and conditions of the Original Contract remain unchanged.

 

/s/ Richard Ferrari   /s/ Steve Foster
Richard Ferrari   Steve Foster
Consultant   President & CEO
     
5/21/2026   5/21/2026
Date Signed   Date Signed

 

Page 1 of 2

 

 

EXHIBIT A

 

DESCRIPTION OF CONSULTING SERVICES AND COMPENSATION

 

a)Consultant's duties under this Agreement shall be to assume the role of Executive Chairman of Tenon Medical.

 

b)For services rendered by Consultant under this Agreement, the Company will pay Richard Ferrari $45,000 quarterly ($180,000 on an annual basis).

 

Page 2 of 2

 

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer